The role of apoptosis in Sjogren's syndrome

Annales de Medecine Interne

Volumn 149, Issue 1, 1998, Pages 25-29

  Bolstad, Anne Isine ^a,b   Jonsson, Roland ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Fas; FasL; Sjogren's syndrome

Indexed keywords

AUTOANTIBODY; FAS ANTIGEN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL DEATH; CHRONIC INFLAMMATION; EXOCRINE GLAND; GENE MUTATION; LYMPHOID CELL; ONCOGENE; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CELLULAR IMMUNITY; EPITHELIUM CELL; HUMAN; IMMUNOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOANTIBODIES; EPITHELIAL CELLS; EXOCRINE GLANDS; FAS LIGAND PROTEIN; HUMANS; IMMUNITY, CELLULAR; MEMBRANE GLYCOPROTEINS; MICE; SJOGREN'S SYNDROME;

EID: 0031987623     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. MOUNTZ JD, ZHOU T, Su X, Wu J, CHENG J. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol, 1996 ; 80 : S2-S14.
2. ARENDS MJ, MORRIS RG, WYLLIE AH. Apoptosis: the role of the endonuclease. Am J Pathol, 1990 ; 136 : 593-608.
3. JACOBSON MD, BURNE JF, RAFF MC. Programmed cell death and Bcl-2 protection in the abscence of a nucleus. EMBO J, 1994 ; 13 : 1899-910.
4. KROEMER G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med, 1997 ; 3 : 614-20.
5. SCHULZE-OSTHOFF K, KRAMMER PH, DRÖGE W. Divergent signaling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 1994 ; 13 : 4587-96.
6. NAGATA S, GOLSTEIN P. The Fas death factor. Science, 1995 ; 267 : 1449-56.
7. THOMPSON CB. Apoptosis in the pathogenesis and treatment of disease. Science, 1995 ; 267 : 1456-62.
8. STELLER H. Mechanisms and genes of cellular suicide. Science, 1995 ; 267 : 1445-9.
9. GUPTA S. Apoptosis/programmed cell death. A historical perspective. Adv Exp Med Biol, 1996 ; 406 : 1-9.
10. HALE AJ, SMITH CA, SUTHERLAND LC et al. Apoptosis: molecular regulation of cell death. Eur J Biochem, 1996 ; 236 : 1-26.
11. FRASER A, EVAN G. A license to kill. Cell, 1996 ; 85 : 781-4.
12. COHEN JJ. Apoptosis and its regulation. Adv Exp Med Biol, 1996 ; 406 : 11-20.
13. TAKAHASHI T, TANAKA M, BRANNAN CI, JENKINS NA, COPELAND NG, SUDA T, NAGATA S. Generalized lympho-proliferative disease in mice caused by a point mutation in the Fas ligand. Cell, 1994 ; 76 : 969-76.
14. CHU JL, DRAPPA J, PARNASSA A, ELKON KB. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon. ETn. J Exp Med, 1993 ; 178 : 723-30.
15. ADACHI M., WATANABE-FUKUNAGA R., NAGATA S. Abberant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA, 1993 ; 90 : 1756-60.
16. WU J, ZHOU T, HE J, MOUNTZ JD. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med, 1993 ; 178 : 461-8.
17. WATANABE-FUKUNAGA R, BRANNAN CI, COPELAND NG, JENKINS NA, NAGATA S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 1992 ; 356 : 314-7.
18. NAGATA S, SUDA T. Fas and Fas ligand: lpr and gld mutations. Immunol Today, 1995 ; 16 : 39-43
19. COHEN PL, EISENBERG RA. Lpr and gld; Single gene models of systemic autoimmunity and lymphoproliferative disorders. Ann Rev Immunol, 1991 ; 9 : 243-69.
20. SKARSTEIN K, NERLAND AH, EIDSHEIM M, MOUNTZ JD, JONSSON R. Lymphoid cell accumulation in salivary glands of autoimmune MRL mice can be due to impaired apoptosis. Scand J Immunol, 1997 ; 46 : 373-8.
21. FISHER GH, ROSENBERG FJ, STRAUS SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 1995 ; 81 : 935-46.
22. RIEUX-LAUCAT F, LE DEIST F, HIVROZ C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 1995 ; 268 : 1347-9.
23. BETTINARDI A, BRUGNONI D, QUIROS-ROLDAN E et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood, 1997 ; 89 : 902-9.
24. WU J, WILSON J, HE J, XIANG L, SCHUR PH, MOUNTZ JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest, 1996 ; 98 : 1107-13.
25. CASCINO I, FIUCCI G, PAPOFF G, RUBERTI G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol, 1995 ; 154 : 2706-13.
26. CHENG J, ZHOU T, LIU C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science, 1994 ; 263 : 1759-62.
27. NOZAWA K, KAYAGAKI N, TOKANO Y, YAGITA H, OKUMURA K, HASIMOTO H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum, 1997 ; 40 : 1126-9.
28. JONSSON R, HALSE AK, SKARSTEIN K et al. Differential expression of apoptosis-related Fas antigen in Sjögren's syndrome. Scand J Immunol, 1994 ; 40 : 705.
29. KONG L, OGAWA N, NAKABAYASHI T et al. FAS and FAS ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum, 1997 ; 40 : 87-97.
30. SUMIDA T, MATSUMOTO I, MURATA H et al. TCR in Fas-sensitive T cells from labial salivary glands of patients with Sjögren's syndrome. J Immunol. 1997 ; 158 : 1020-5.
31. JONSSON R, BOLSTAD AI, NERLAND AH, SKARSTEIN K. Decreased apoptosis in situ in clinical and experimental Sjögren's syndrome. Arthritis Rheum, 1996 ; 39 (suppl.) : S289.
32. POLIHRONIS M, TAPINOS NI, THEOCHARIS SE, KITTAS C, MOUTSOPOULOS HM. Modes of epithelial cell death and repair in Sjögren's syndrome. Arthritis Rheum, 1997 ; 40 (suppl) : S224.
33. ICHIKAWA Y, ARIMORI K, YOSHIDA M, et al. Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjögren's syndrome. Clin Exp Rheumatol, 1995 ; 13 : 307-13.
34. ROBINSON CP, YAMACHIKA S, ALFORD CE, et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjögren's syndrome. Proc Natl Acad Sci USA, 1997 ; 94 : 5767-71.
35. SMYTH MJ, TRAPANI JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today, 1995 ; 16 : 202-6
36. ALPERT S, KANG HI, WEISSMAN I, Fox RI. Expression of granzyme A in salivary gland biopsies from patients with primary Sjögren's syndrome. Arthritis Rheum, 1994 ; 37 : 1046-54.
37. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med, 1994 ; 179 : 1317-30.
38. TAN EM. Autoimmunity and apoptosis. J Exp Med, 1994 ; 179 : 1083-6.
39. UTZ PJ, HOTTELET M, SCHUR PH, ANDERSON P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantiboy production in patients with systemic lupus erythematosus. J Exp med, 1997 ; 185 : 843-54.
40. WU J, ZHOU T, ZHANG J, HE J, GAUSE WC, MOUNTZ JD. Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci USA, 1994 ; 91 : 2344-8.
41. ADACHI M, SUEMATSU S, KONDO T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet, 1995 ; 11 : 294-9.